WEScover: selection between clinical whole exome sequencing and gene panel testing.

BMC Bioinformatics

Computational Health Informatics Program, Boston Children's Hospital, 401 Park Drive, Mail Stop BCH3187, LM5528.4, Boston, MA, 02115, USA.

Published: May 2021


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Whole exome sequencing (WES) is widely adopted in clinical and research settings; however, one of the practical concerns is the potential false negatives due to incomplete breadth and depth of coverage for several exons in clinically implicated genes. In some cases, a targeted gene panel testing may be a dependable option to ascertain true negatives for genomic variants in known disease-associated genes. We developed a web-based tool to quickly gauge whether all genes of interest would be reliably covered by WES or whether targeted gene panel testing should be considered instead to minimize false negatives in candidate genes.

Results: WEScover is a novel web application that provides an intuitive user interface for discovering breadth and depth of coverage across population-scale WES datasets, searching either by phenotype, by targeted gene panel(s) or by gene(s). Moreover, the application shows metrics from the Genome Aggregation Database to provide gene-centric view on breadth of coverage.

Conclusions: WEScover allows users to efficiently query genes and phenotypes for the coverage of associated exons by WES and recommends use of panel tests for the genes with potential incomplete coverage by WES.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139020PMC
http://dx.doi.org/10.1186/s12859-021-04178-5DOI Listing

Publication Analysis

Top Keywords

gene panel
12
panel testing
12
targeted gene
12
exome sequencing
8
false negatives
8
breadth depth
8
depth coverage
8
genes
6
wes
5
wescover selection
4

Similar Publications

Introduction Neuroendocrine tumors (NETs) are a rare and heterogeneous group of neoplasms with both clinical and genetic diversity. The clinical applicability of molecular profiling using liquid biopsy for identifying actionable drug targets and prognostic indicators in patients with advanced NETs remains unclear. Methods In this study, we utilized a custom-made 37 genes panel of circulating tumor DNA (ctDNA) based on next-generation sequencing (NGS) in 47 patients with advanced NETs.

View Article and Find Full Text PDF

Introduction: Congenital Hypogonadotropic Hypogonadism (CHH) arises from defects in the synthesis, secretion, or action of gonadotropin-releasing hormone (GnRH), resulting in incomplete or absent pubertal development and various non-reproductive features. CHH is genetically heterogeneous, with over 50 genes implicated in its pathogenesis. This study aimed to elucidate the genetic variants of CHH in a cohort of patients from a single-center endocrinology unit.

View Article and Find Full Text PDF

Background: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood. For stratification purposes, rhabdomyosarcoma is classified into fusion-positive RMS (alveolar rhabdomyosarcoma) and fusion-negative RMS (embryonal or spindle cell/sclerosing, FN-RMS) subtypes according to its fusion status. This study aims to highlight the pathologic and molecular characteristics of a cohort of FN-RMS using a targeted NGS RNA-Seq assay.

View Article and Find Full Text PDF

Objective: The key molecular events signifying the -induced gastric carcinogenesis process are largely unknown.

Methods: Bulk tissue-proteomics profiling were leveraged across multi-stage gastric lesions from Linqu ( = 166) and Beijing sets ( = 99) and single-cell transcriptomic profiling ( = 18) to decipher key molecular signatures of -related gastric lesion progression and gastric cancer (GC) development. The association of key proteins association with gastric lesion progression and GC development were prospectively studied building on follow-up of the Linqu set and UK Biobank ( = 48,529).

View Article and Find Full Text PDF

Background: Polygenic risk scores (PRS) are not yet standard in clinical risk assessments for familial breast cancer in Sweden. This study evaluated the distribution and impact of an established PRS (PRS) in women undergoing clinical sequencing for hereditary breast cancer.

Findings: We integrated PRS into a hereditary breast cancer gene panel used in clinical practice and calculated scores for 262 women.

View Article and Find Full Text PDF